Market Data
Market Cap₹1,174.34 Cr.
52W High₹770
Current Price₹586.3
52W Low₹439.95
Down from 52W High23.9 %
Face Value₹10
Performance
ROCE16.91 %
ROE12.73 %
EPS (TTM)₹18.09
EPS Prev Qtr₹5.81
EPS Last Year₹9.98
EBITDA Qtr₹23.55 Cr.
Book Value₹378
Financial Health
Debt/Equity0.01
Debt/Profit0.05
Total Assets₹890.4 Cr.
Dividend Yield0.31 %
Promoter Holding49.78 %
Earning Power9.7 %
Valuation
Stock P/E12.17
Industry P/E33.3
Price to Book1.55
Price to Sales1.69
Graham Number₹640.22
Key Metrics
__derived
1
Face Value
₹10
About Lincoln Pharmaceuticals Ltd
Healthcare · Pharmaceuticals
Lincoln Pharmaceuticals Ltd is listed on NSE in the Healthcare / Pharmaceuticals sector. Face value ₹10. Market cap ₹1,174.34 Cr.
Price Chart
Strengths & Weaknesses
Strengths
- The company has a strong ROCE of 19.18%, indicating efficient use of capital.
- The company boasts a healthy ROE of 14.36%, reflecting good return generation for shareholders.
- With a debt-to-equity ratio of 0, the company is free from financial leverage risks.
- The promoter holding stands at 49.78%, suggesting significant management control and alignment of interests.
Weaknesses
- The dividend yield is low at 0.3%, which may not attract income-focused investors.
- The P/E ratio of 12.27 may indicate that the stock is fairly valued or potentially overvalued relative to earnings.
Peer Comparison
| Name | CMP | P/E | Market Cap | Div Yield | NP Qtr | Qtr Profit Var% | Sales Qtr | Qtr Sales Var% | ROCE% | Debt/Eq |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | - | 36.9 | ₹4,46,276.3 Cr | 0.86% | ₹12,172.7 Cr | - | ₹59,910.52 Cr | - | 18.72% | 0.05 |
| Divis Laboratories Ltd | - | 85.97 | ₹2,51,531.48 Cr | 0.32% | ₹2,925 Cr | - | ₹11,230 Cr | - | 23.04% | 0 |
| Torrent Pharmaceuticals Ltd | - | 78.4 | ₹1,86,956.51 Cr | 0.77% | ₹2,156 Cr | - | ₹15,723 Cr | - | 15.1% | 1.76 |
| Zydus Lifesciences Ltd | - | 26.64 | ₹1,19,221.66 Cr | 0.08% | ₹4,492.2 Cr | - | ₹28,591.7 Cr | - | 16.76% | 0.43 |
| Cipla Ltd | - | 33.13 | ₹1,11,725.01 Cr | 0.94% | ₹3,364.84 Cr | - | ₹28,324.4 Cr | - | 13.24% | 0.01 |
| Laurus Labs Ltd | - | 98.01 | ₹1,07,271.96 Cr | 0.06% | ₹1,090.76 Cr | - | ₹7,269.64 Cr | - | 20.79% | 0.45 |
| Mankind Pharma Ltd | - | 51.42 | ₹1,05,107.48 Cr | 0.04% | ₹2,067.57 Cr | - | ₹14,737.88 Cr | - | 13.95% | 0.38 |
| Dr Reddys Laboratories Ltd | - | 32.31 | ₹1,04,334.48 Cr | 0.64% | ₹3,183.3 Cr | - | ₹33,227.9 Cr | - | 10.05% | 0.17 |
| Aurobindo Pharma Ltd | - | 26.61 | ₹97,986.86 Cr | 0.23% | ₹3,710.8 Cr | - | ₹34,935.29 Cr | - | 12.75% | 0.2 |
| Lupin Ltd | - | 16.63 | ₹94,189.9 Cr | 0.87% | ₹5,550.99 Cr | - | ₹29,966.58 Cr | - | 27.95% | 0.26 |
| Glenmark Pharmaceuticals Ltd | - | 37.59 | ₹67,587.09 Cr | 0.1% | ₹1,797.81 Cr | - | ₹17,736.56 Cr | - | 24.78% | 0.25 |
| Alkem Laboratories Ltd | - | 29.02 | ₹62,609.02 Cr | 1.01% | ₹2,206.3 Cr | - | ₹15,081.28 Cr | - | 19.75% | 0.12 |
| Biocon Ltd | - | 111.18 | ₹61,602.44 Cr | 0.13% | ₹416.4 Cr | - | ₹17,321.1 Cr | - | 2.87% | 0.43 |
| Abbott India Ltd | - | 35.88 | ₹57,939.73 Cr | 1.74% | ₹1,614.68 Cr | - | ₹7,004.38 Cr | - | 45.73% | 0 |
| Gland Pharma Ltd | - | 43.62 | ₹49,299.85 Cr | 0.67% | ₹1,128.8 Cr | - | ₹6,725.3 Cr | - | 15.21% | 0.02 |
| Ipca Laboratories Ltd | - | 36.55 | ₹49,280.78 Cr | 0.31% | ₹1,379.76 Cr | - | ₹10,125.58 Cr | - | 21.48% | 0.09 |
| Anthem Biosciences Ltd | - | 85 | ₹49,084.9 Cr | 0.23% | ₹575.95 Cr | - | ₹2,002.34 Cr | - | 25.5% | 0.02 |
| Glaxosmithkline Pharmaceuticals Ltd | - | 44.95 | ₹47,217.7 Cr | 2.05% | ₹1,068.15 Cr | - | ₹3,954.94 Cr | - | 64.07% | 0 |
| Ajanta Pharma Ltd | - | 39.17 | ₹44,452.1 Cr | 0.79% | ₹1,134.88 Cr | - | ₹5,776.17 Cr | - | 31.81% | 0.05 |
| J B Chemicals & Pharmaceuticals Ltd | - | 53.3 | ₹38,730.77 Cr | 0.39% | ₹709.46 Cr | - | ₹4,147.79 Cr | - | 23.03% | 0 |
Quarterly Results
📊 Jun 2026: Revenue grew 15.1% YoY, Profit grew 30.9% YoY
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 154.07 | 163.36 | 166.32 | 187.28 | 177.28 |
| ↳ QoQ Growth | - | +6.0% | +1.8% | +12.6% | -5.3% |
| Expenses | 133.74 | 141.55 | 146.45 | 166.11 | 153.73 |
| Operating Profit | 20.33 | 21.81 | 19.88 | 21.17 | 23.55 |
| OPM % | 13.2% | 13.35% | 11.95% | 11.3% | 13.28% |
| Other Income | 15.27 | 7.23 | 15.15 | -4.2 | 24.26 |
| Interest | 0.21 | 0.23 | 0.3 | 0.27 | 0.26 |
| Depreciation | 3.48 | 3.62 | 3.72 | 3.68 | 3.88 |
| EBITDA | 23.81 | 25.43 | 23.6 | 24.85 | 27.43 |
| EBITDA Margin % | 15.45% | 15.57% | 14.19% | 13.27% | 15.47% |
| Profit Before Tax | 35.39 | 28.81 | 34.72 | 16.7 | 47.55 |
| Tax % | 21.79% | 30.65% | 17.63% | 30.36% | 23.81% |
| Net Profit | 27.68 | 19.98 | 28.6 | 11.63 | 36.23 |
| ↳ QoQ Growth | - | -27.8% | +43.1% | -59.3% | +211.5% |
| EPS | 13.81 | 9.98 | 14.28 | 5.81 | 18.09 |
Profit & Loss
| Mar 2026 | TTM | |
|---|---|---|
| Sales | 671.03 | 694.24 |
| Expenses | 587.85 | 607.84 |
| Operating Profit | 83.19 | 86.41 |
| OPM % | 12.4% | 12.45% |
| Other Income | 33.45 | 42.44 |
| Interest | 1.01 | 1.06 |
| Depreciation | 14.5 | 14.9 |
| Profit Before Tax | 115.62 | 127.78 |
| Tax % | 23.98% | 24.53% |
| Net Profit | 87.89 | 96.44 |
| EPS | 43.88 | 48.16 |
Compounded Sales Growth
10Y
-
5Y
-
3Y
-
TTM
-
Compounded Profit Growth
10Y
-
5Y
-
3Y
-
TTM
-
Stock Price CAGR
10Y
-
5Y
-
3Y
-
1Y
10.06%
Return on Equity
10Y
-
5Y
-
3Y
-
Last Year
14.36%
Balance Sheet
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 20.0297 | 20.03 |
| Reserves | 651.6389 | 737.6 |
| Borrowings | 0 | 4.42 |
| Other Liabilities | 125.34 | 128.35 |
| Total Liabilities | 797.0059 | 890.4 |
| Fixed Assets | 181.969 | 190.03 |
| CWIP | 4.4696 | 5.23 |
| Investments | 173.72 | 208.54 |
| Other Assets | 436.85 | 486.6 |
| Total Assets | 797.0059 | 890.4 |
Cash Flows
| Mar 2025 | |
|---|---|
| Cash from Operating Activity | 93.0155 |
| Cash from Investing Activity | -78.9474 |
| Cash from Financing Activity | -6.4015 |
| Net Cash Flow | 7.6666 |
Ratios
| Mar 2026 | |
|---|---|
| Debtor Days | - |
| Inventory Days | - |
| Days Payable | - |
| Cash Conversion Cycle | - |
| Working Capital Days | 481.92 |
| ROCE % | 9.39% |
Shareholding Pattern
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Promoters % | 49.78% | 49.78% | 49.78% | 49.78% |
| FIIs % | 4.72% | 4.7% | 5.19% | 4.6% |
| DIIs % | 0.01% | 0.01% | 1.08% | 0.27% |
| Public % | 36.26% | 36.29% | 34.7% | 36.12% |
| No. of Shareholders | 32,370 | 31,026 | 28,303 | 29,396 |
Major Shareholders (>1%)
- Munjal Mahendrabhai PatelPromoter and Promoter Group13.37%
- Ashish Rajanikant PatelPromoter and Promoter Group10.60%
- Rajanikant Gulabdas PatelPromoter and Promoter Group3.78%
- Mahendrabhai Gulabdas PatelPromoter and Promoter Group3.37%
As of 2026-06-30View all shareholders →